Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions

Psychiatric Services

Volumn 59, Issue 4, 2008, Pages 384-391

  Yang, Hui Wen Keri ^a   Simoni Wastfla, Linda ^a,b   Zuckerman, Ilene H ^a,b   Stuart, Bruce ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b Peter Lamy Center on Drug Therapy and Aging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CHLORDIAZEPOXIDE; ESTAZOLAM; FLURAZEPAM; LORAZEPAM; OXAZEPAM; QUAZEPAM; TEMAZEPAM; TRIAZOLAM; BENZODIAZEPINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; DEPRESSION; DRUG COST; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICARE; MENTAL DISEASE; PRESCRIPTION; SEX DIFFERENCE; ECONOMICS; HEALTH CARE COST; INSURANCE; MENTAL HEALTH SERVICE; MIDDLE AGED; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

AGED; AGED, 80 AND OVER; BENZODIAZEPINES; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE COVERAGE; MALE; MEDICARE PART D; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MIDDLE AGED; UNITED STATES;

EID: 85047684620     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.2008.59.4.384     Document Type: Article

References (28)

1. Bambauer KZ, Sabin JE, Soumerai SB: The exclusion of benzodiazepine coverage in Medicare: simple steps for avoiding a public health crisis. Psychiatric Services 56: 1143-1146, 2005
2. Critical Coverage: Benzodiazepines Under Medicare Part D. New York, Medicare Rights Center, June 2005. Available at www.medicarerights.org/ benzoreport.pdfPtr=y&auid=9084566
3. IMS Health: Top 10 Therapeutic Classes by US Dispensed Prescriptions. Norwalk, Conn, IMS Health, 2007. Available at www.imshealth.com/ims/portal/ front/articleC/0,2777,65998041180880413635,00.html
4. Stefanacci RG: The Cost of Being Excluded: Impact of Excluded Medications Under Medicare Part D on Dually Eligible Nursing Home Residents. Available at archive. ascp.com/MedicareRx/docs/ASCPPaperExcludedMeds.pdf
5. Bruce SE, Vasile RG, Goisman RM, et al: Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? American Journal of Psychiatry 160:1432-1438, 2003
6. Shader RI, Greenblatt DJ: Use of benzodiazepines in anxiety disorders. New England Journal of Medicine 328:1398-1405, 1993
7. American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). American Journal of Psychiatry 159(Apr suppl):1-50, 2002
8. Pollack MH: The pharmacotherapy of panic disorder. Journal of Clinical Psychiatry 66:23-27, 2005
9. Rosenbaum JF: Attitudes toward benzodiazepines over the years. Journal of Clinical Psychiatry 66:4-8, 2005
10. Alldredge BK, Gelb AM, Isaacs SM, et al: A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. New England Journal of Medicine 345:631-637, 2001
11. WHO Model List of Essential Medicines, 14th ed (revised March 2005). Geneva, World Health Organization, March 2005. Available at whqlibdoc.who.int/ hq/2005/a87017eng.pdf
12. American Psychiatric Association: Benzodiazepine Dependence, Toxicity, and Abuse: A Task Force Report of the American Psychiatric Association. Washington, DC, American Psychiatric Publishing, 1990
13. Fick DM, Cooper JW, Wade WE, et al: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Archives of Internal Medicine 163:2716-2724, 2003
14. Wagner AK, Zhang F, Sonmerai SB, et al: Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? Archives of Internal Medicine 164:1567-1572, 2004
15. Simoni-Wastila L, Ross-Degnan D, Mah C, et al: A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in Medicaid patients with chronic psychiatric and neurologic disorders. Clinical Therapeutics 26:322-336, 2004
16. Pearson S-A, Sonmerai S, Mah C, et al: Racial disparities in access following regulatory surveillance of benzodiazepines. Archives of Internal Medicine 166:572-579, 2006
17. Ross-Degnan D, Simoni-Wastila L, Brown J, et al: A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. International Journal of Psychiatry in Medicine 34:102-123, 2004
18. Rickels K, Schweizer E, Case W, et al: Long-term therapeutic use of benzodiazepines: I. effects of abrupt discontinuation. Archives of General Psychiatry 47:899-907, 1990
19. Medicare Current Beneficiary Survey. Baltimore, Centers for Medicare and Medicaid Services. Available at www.cms.hhs.gov/apps/mcbs
20. Pope GC, Kautter J, Ellis RP, et al: Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financing Review 25:119-141, 2004
21. Simoni-Wastila L, Zuckerman I, Shaffer T, et al: Drug use patterns in severely mentally ill Medicare beneficiaries: impact of discontinuities in drug coverage. Health Services Research, in press
22. Khandker R, Simoni-Wastila L: Differences in Medicaid utilization of prescription drugs between blacks and whites in the Georgia Medicaid population. Inquiry 35:78-87, 1998
23. Simoni-Wastila L: The use of abusable prescription drugs: the role of gender. Journal of Women's Health and Gender-Based Medicine 9:289-297, 2000
24. Stuart B, Simoni-Wastila L, Chauncey D: Assessing the impact of coverage gaps in the Medicare Part D drug benefit. Health Affairs (Web Exclusives suppl):W5-167-W5-179, 2005
25. Tseng CW, Brook RH, Keeler E, et al: Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA 292:952-960, 2004
26. Augustin SG : Anxiety disorders, in Applied Therapeutics: The Clinical Use of Drugs, 8th ed. Edited by Koda-Kimble MA, Young LY, Kradian WA, et al. Philadelphia, Lippincott Williams and Willkins, 2005
27. Eadie JL: New York States Triplicate Prescription Program, in Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care. Edited by Cooper JR, Czechowitcz DJ, Molinari SP, et al. Rockville, Md, National Institute on Drug Abuse, 1993. Available at www.nida.nih.gov/pdf/ monographs/131.pdf
28. Wagner AK, Ross-Degnan D, Gurwitz JH, et al: Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. Annals of Internal Medicine 146:96-103, 2007